Background/Aims: Kabuki syndrome (KS) is a rare genetic malformation syndrome, resulting in characteristic features such as short stature. We investigate whether growth hormone (GH) treatment increases linear height and influences body proportions in KS children. Methods: In this prospective study, 18 genetically confirmed prepubertal KS children (9 females and 9 males) aged from 3.8 to 10.1 years (mean 6.8 ± 2.1 years) were treated with recombinant human GH (rhGH) for 1 year. Calculations for height, height velocity, BMI, sitting height, and subischial leg length were made. Bone age, insulin-like growth factor (IGF-I), and IGF binding protein 3 (IGFBP-3) were also measured. Results: This study showed an increase in height standard deviation score (SDS) for the whole group from –2.40 to –1.69 (p < 0.05) after 1 year of rhGH treatment. The change in height SDS within 1 year was >0.7 SDS for 10 subjects and >0.5 SDS for 3 subjects. The mean IGF-I SDS at the start of the study was –0.70 (±1.07), which increased after 12 months to 1.41 (±0.91) (p < 0.05). KS children who received rhGH at a younger age displayed significantly greater increases in height than those who started when they were older. The same was true for both gene mutation KMT2D versus KDM6A and for GH deficiency versus non-GH deficiency KS children (p < 0.05). Throughout the course of rhGH treatment, the subjects’ body proportions remained normal. Conclusions: All participants experienced catch-up growth during the year of rhGH treatment, but without an influence on body proportions.

1.
Kuroki Y, Suzuki Y, Chyo H, et al: A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr 1981; 99:570–573.
2.
Niikawa N, Matsuura N, Fukushima Y, et al: Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr 1981; 99:565–569.
3.
Ng SB, Bigham AW, Buckingham KJ, et al: Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 2010; 42:790–793.
4.
Paulussen AD, Stegmann AP, Blok MJ, et al: MLL2 mutation spectrum in 45 patients with Kabuki syndrome. Hum Mutat 2011; 32:E2018–E2025.
5.
Schott DA, Blok MJ, Gerver WJ, et al: Growth pattern in Kabuki syndrome with a KMT2D mutation. Am J Med Genet A 2016; 170:3172–3179.
6.
Devriendt K, Lemli L, Craen M, et al: Growth hormone deficiency and premature thelarche in a female infant with kabuki makeup syndrome. Horm Res 1995; 43:303–306.
7.
Gabrielli O, Bruni S, Bruschi B, et al: Kabuki syndrome and growth hormone deficiency: description of a case treated by long-term hormone replacement. Clin Dysmorphol 2002; 11:71–72.
8.
Handa Y, Maeda K, Toida M, et al: Kabuki make-up syndrome (Niikawa-Kuroki syndrome) with cleft lip and palate. J Craniomaxillofac Surg 1991; 19:99–101.
9.
Tawa R, Kaino Y, Ito T, et al: A case of Kabuki make-up syndrome with central diabetes insipidus and growth hormone neurosecretory dysfunction. Acta Paediatr Jpn 1994; 36:412–415.
10.
Tanner J: Growth at Adolescence. Oxford, Blackwell, 1962.
11.
Greulich W, Pyle S: Radiographic Atlas of Skeletal Development of the Hand and Wrist. Standford, Standford University Press, 1959.
12.
Schott DA, Gerver WJ, Stumpel CT: Growth hormone stimulation tests in children with Kabuki syndrome. Horm Res Paediatr 2016; 86:319–324.
13.
Bidlingmaier M, Friedrich N, Emeny RT, et al: Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 2014; 99:1712–1721.
14.
Friedrich N, Wolthers OD, Arafat AM, et al: Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab 2014; 99:1675–1686.
15.
Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child 1966; 41:454–471.
16.
Talma H, Schnbeck Y, Bakker B, et al: Groei-diagrammen 2010. TNO Kwaliteit van Leven, Leiden, 2010.
17.
Hermanussen M, Cole J: The calculation of target height reconsidered. Horm Res 2003; 59:180–183.
18.
Gerver WJM, de Bruin R (eds): Paediatric Morphometrics, a Reference Manual, ed 2. Utrecht, Bunge, 2001.
19.
Growth Hormone Research Society: Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000; 85:3990–3993.
20.
Clayton PE, Cianfarani S, Czernichow P, et al: Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007; 92:804–810.
21.
Van den Broeck J, Massa GG, Attanasio A, et al: Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. J Pediatr 1995; 127:729–735.
22.
Nilsson KO, Albertsson-Wikland K, Alm J, et al: Improved final height in girls with Turner’s syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996; 81:635–640.
23.
Rosenfeld RG, Frane J, Attie KM, et al: Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992; 121:49–55.
24.
Board KI: Kabi International Growth Hormone Study (KIGS – Pfizer International Growth Database). https://medicaloutcomes.pfizer.com.
25.
Niikawa N, Kuroki Y, Kajii T, et al: Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients. Am J Med Genet 1988; 31:565–589.
26.
Banka S, Veeramachaneni R, Reardon W, et al: How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum. Eur J Hum Genet 2012; 20:381–388.
27.
Rosenfeld RG: Biochemical diagnostic strategies in the evaluation of short stature: the diagnosis of insulin-like growth factor deficiency. Horm Res 1996; 46:170–173.
28.
Cianfarani S, Tondinelli T, Spadoni GL, et al: Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? Clin Endocrinol (Oxf) 2002; 57:161–167.
29.
Sas TC, Gerver WJ, de Bruin R, et al: Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose-response trial. J Clin Endocrinol Metab 1999; 84:4622–4628.
30.
Schweizer R, Ranke MB, Binder G, et al: Experience with growth hormone therapy in Turner syndrome in a single centre: low total height gain, no further gains after puberty onset and unchanged body proportions. Horm Res 2000; 53:228–238.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.